RNAi modulation of TGF-beta and therapeutic uses thereof
View Patent ↗The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.
1. An isolated iRNA agent, comprising an antisense strand and a sense strand complementary to said antisense strand, wherein the antisense strand comprises SEQ ID NO:88 (cmaaugumacmagcugccgcmacTT*), wherein cm is 2′-O-methylcytidine-5′-monophosphate, wherein um is 2′-O-methyl-uridine-5′-monophosphate, and wherein T* is deoxythymidine 5′-monothiophosphate.
2. The iRNA agent of claim 1 , wherein said iRNA agent mediates the cleavage of a TGF-beta mRNA within the target sequence iRNA agent AL-DP-6858.
3. The iRNA agent of claim 1 , wherein the iRNA agent further comprises a non-nucleotide moiety.
4. The iRNA of claim 1 , wherein the sense and/or antisense strand is further stabilized against nucleolytic degradation.
5. The iRNA agent of claim 1 , wherein the sense strand further comprises at least one 3′-overhang wherein said 3′-overhang comprises from 1 to 6 nucleotides.
6. The iRNA agent of claim 1 , further comprising a phosphorothioate at the first internucleotide linkage at the 5′ end of the sense strand.
7. The iRNA agent of claim 6 , further comprising a phosphorothioate at the first internucleotide linkage at the 3′ end of the sense strand.
8. The iRNA agent of claim 1 , further comprising a 2′-modified nucleotide in the sense strand.
9. The iRNA agent of claim 8 , wherein the 2′-modified nucleotide comprises a modification selected from the group consisting of: 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), and 2′-O—N-methylacetamido (2′-O—NMA).
10. The iRNA agent of claim 1 , wherein said sense strand is 21 contiguous nucleotides of the sense sequence of iRNA agent AL-DP-6858 (SEQ ID NO:85).
11. The iRNA agent of claim 1 , wherein said sense strand comprises SEQ ID NO:85.
12. The iRNA agent of claim 1 , wherein said sense strand consists of SEQ ID NO:85.
13. The iRNA agent of claim 1 , wherein the iRNA agent is AL-DP-6271.
14. The iRNA agent of claim 1 , wherein the antisense consists of SEQ ID NO:88 (cmaaugumacmagcugccgcmacTT*), wherein cm is 2′-O-methylcytidine-5′-monophosphate, wherein um is 2′-O-methyl-uridine-5′-monophosphate, and wherein T* is deoxythymidine 5′-monothiophosphate.
15. The iRNA agent of claim 1 , wherein the iRNA agent comprises AL-DP-6271.
16. An isolated iRNA agent, comprising an antisense strand and a sense strand complementary to said antisense strand, wherein the sense strand comprises SEQ ID NO:87 (gumgcmggcmagcmumgumacmaumumgTT*), wherein cm is 2′-O-methylcytidine-5′-monophosphate, wherein um is 2′-O-methyl-uridine-5′-monophosphate, and wherein T* is deoxythymidine 5′-monothiophosphate.
17. The iRNA agent of claim 16 , wherein the sense strand consists of SEQ ID NO:87 (gumgcmggcmagcmumgumacmaumumgTT*), wherein cm is 2′-O-methylcytidine-5′-monophosphate, wherein um is 2′-O-methyl-uridine-5′-monophosphate, and wherein T* is deoxythymidine 5′-monothiophosphate.
18. An isolated iRNA agent, comprising an antisense strand and a sense strand complementary to said antisense strand, wherein the sense strand comprises SEQ ID NO:87 (gumgcmggcmagcmumgumacmaumumgTT*) and the antisense strand comprises SEQ ID NO:88 (cmaaugumacmagcugccgcmacTT*), wherein cm is 2′-O-methylcytidine-5′-monophosphate, wherein um is 2′-O-methyl-uridine-5′-monophosphate, and wherein T* is deoxythymidine 5′-monothiophosphate.
19. The iRNA agent of claim 18 , wherein the sense strand consists of SEQ ID NO:87 (gumgcmggcmagcmumgumacmaumumgTT*) and the antisense strand consists of SEQ ID NO:88 (cmaaugumacmagcugccgcmacTT*), wherein cm is 2′-O-methylcytidine-5′-monophosphate, wherein um is 2′-O-methyl-uridine-5′-monophosphate, and wherein T* is deoxythymidine 5′-monothiophosphate.
20. A vector encoding the iRNA agent of claim 1 .
21. A cell comprising the iRNA agent of claim 1 or the vector of claim 20 .
22. A method of making the iRNA agent of claim 1 , the method comprising the synthesis of the iRNA agent, wherein the sense and antisense strands comprise at least one modification that stabilizes the iRNA agent against nucleolytic degradation.
23. A pharmaceutical composition comprising the iRNA agent of claim 1 and a pharmaceutically acceptable carrier.
24. A method of treating a human diagnosed as having a disease or disorder associated with undesired TGF-beta signaling, comprising administering to a subject in need of such treatment a therapeutically effective amount of the iRNA agent of claim 1 .
25. The method of claim 24 , wherein the human is diagnosed as having idiopathic pulmonary fibrosis, diabetic nephropathy or chronic liver disease.
26. A method of reducing the levels of a TGF-beta mRNA in a cell of a subject, or of TGF-beta protein secreted by a cell of a subject, comprising the step of administering the iRNA agent of claim 1 to said subject.
27. The method of claim 26 wherein said iRNA agent mediates the cleavage of a TGF-beta mRNA within the target sequence of iRNA agent AL-DP-6858.
28. The method of claim 26 , wherein said iRNA agent is administered to the subject.
29. The method of claim 28 , wherein said administration comprises pulmonary administration.
30. The method of claim 26 , wherein the level of TGF-beta protein and/or TGF-beta mRNA is reduced by at least 20%.
31. The method of claim 26 , wherein said sense strand is 21 contiguous nucleotides of the sense sequence of iRNA agent AL-DP-6858 (SEQ ID NO:85).
32. A method of reducing the levels of a TGF-beta mRNA in a cell, or of TGF-beta protein secreted by a cell, comprising contacting the cell with the iRNA agent of claim 1 .